Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. develops and commercializes medical technology and healthcare services for breathing-related sleep disorders, including obstructive sleep apnea and snoring associated with dentofacial abnormalities. Its Complete Airway Repositioning and Expansion (CARE) oral devices have FDA 510(k) clearances for adult OSA patients across severity levels and for moderate-to-severe OSA in children ages 6 to 17.
Company news commonly covers financial results, sleep testing services, treatment-center activity, and the integration of The Sleep Center of Nevada operating assets. Updates also address the shift toward a medical-affiliation distribution model, payer-network status for supported professional practices, collaborations for airway and sleep technologies, and capital actions such as warrant exercises and private placements.
Vivos Therapeutics (NASDAQ: VVOS) plans to release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and will host a conference call at 5:00 p.m. Eastern Time to review results and provide operational updates.
Participants can join the investor call by dialing (800) 717-1738 in the U.S. or (646) 307-1865 internationally. A replay will be available until Friday, August 28, 2026 at (844) 512-2921 or (412) 317-6671 (passcode 1174558). A live webcast and 30-day archive will be accessible at https://vivos.com/investors/. Vivos is a medical technology and healthcare services company focused on FDA-cleared diagnostic and treatment devices for obstructive sleep apnea and related breathing disorders in adults and children.
Vivos Therapeutics (NASDAQ: VVOS) announced an expanded strategic engagement with Greenway Health to deploy Greenway’s AI-by-design Novare platform across Vivos’ clinical and revenue-cycle operations, beginning with Sleep Centers of Nevada (SCN). Greenway’s analysis estimates Novare and related workflow automation could potentially generate about $9.1 million in annual value for Vivos at SCN.
According to Vivos, this includes roughly $8.0 million from increased patient capacity and $1.0 million from revenue-cycle improvements in Nevada, plus up to $1.8 million in annual savings from recovering an estimated 46,000+ labor hours and creating capacity for nearly 30,000 additional patient visits. Vivos plans to extend Novare to new markets in Arizona and Florida, aiming to increase operating leverage by integrating AI-driven clinical documentation, eligibility checks, coding assistance, prior-authorization automation and denial-reduction tools, while limiting growth in administrative headcount.
Vivos Therapeutics (NASDAQ: VVOS) announced that the US Patent and Trademark Office has issued US Patent No. 12,697,190, titled “Vibrational Oral Appliance with Mandibular Advancements.” This continuation of the 2024 foundational Patent No. 12,048,608 broadens protection for the company’s Vivos CARE vibrational oral appliance platform.
The ’190 Patent adds broader, design‑independent claims while the ’608 Patent maintains detailed, structure‑specific coverage, giving Vivos layered intellectual property protection around its core technology. According to Vivos, its CARE oral devices are the only FDA 510(k) cleared oral appliances for treating severe OSA in adults and moderate to severe OSA in children ages 6–17. Studies cited by the company indicate that about 80% of patients treated with Vivos CARE devices achieve significant reductions or complete resolution of OSA symptoms, measured by standard AHI scores. Vivos believes this expanded patent estate strengthens its competitive position in a large, underdiagnosed global sleep apnea market.
Vivos Therapeutics (NASDAQ: VVOS) reported new clinical data on its FDA-cleared Vida® oral appliance for patients with longstanding moderate to severe insomnia.
In a 37-patient single-site study, average Insomnia Severity Index scores fell about 65%, with 100% improving at least one severity level and ending with no or subthreshold insomnia (p≈0.0000001). Vivos sees a potential new insomnia revenue stream, including an estimated $36 million annual addressable market at Sleep Centers of Nevada alone, though it notes the data are early and insomnia-related findings are not FDA-reviewed.
Vivos Therapeutics (NASDAQ: VVOS) extended its strategic financing agreement with Streeterville Capital through August 31, 2026.
Streeterville reaffirmed its commitment to convert up to $4.5 million of debt into a mix of perpetual, non-convertible preferred stock and common stock once Vivos raises $2.6 million, supporting Nasdaq listing compliance and a planned rights offering.
Vivos Therapeutics (NASDAQ: VVOS) plans to file a registration statement with the SEC for a proposed transferable rights offering. Shareholders of record, 30 days after SEC effectiveness, are expected to receive rights as a dividend.
Each right is expected to allow purchase of one common share at the greater of $1.25 or 20% above market, be listed for trading, and be exercisable for nine months. Exercising a right is expected to grant a subsequent nine‑month right with an exercise price set at the greater of $1.75 or 40% above market. Completion depends on multiple conditions, and Vivos notes there is no assurance the offering will commence or be completed.
Vivos Therapeutics (NASDAQ: VVOS) announced a collaboration agreement with South Palm Cardiovascular Associates to form AIM Florida, a management services organization focused on diagnosing and treating obstructive sleep apnea and insomnia in cardiovascular patients.
Vivos expects to own at least 80% of AIM Florida, with SPCVA up to 20%. The initial Sleep Optimization Team is planned to serve about 250 patients per month and is projected to generate over $6 million in annual revenue with contribution margins approaching 50%, based on Vivos’ prior Las Vegas experience. Operations will initially target Palm Beach County, with potential expansion across Florida and to other cardiology and specialty practices, subject to definitive agreements and regulatory compliance.
Vivos Therapeutics (NASDAQ: VVOS) announced that its executive team will participate in The Small Cap Showcase & WTR Insights on June 9, 2026, in New York City.
CEO Kirk Hunstman will present at 11:30 am ET, with a live and replay webcast available via the company’s investor relations website.
Vivos Therapeutics (NASDAQ: VVOS) agreed with senior lender Streeterville Capital to exchange up to $4.5 million of debt into perpetual, nonconvertible preferred stock and common shares. The exchange, contingent on qualifying equity financings, is intended to bolster stockholders’ equity, support Nasdaq listing compliance, and reduce debt service.
Streeterville committed to suspend debt repayment calls for 90 days and sales of Vivos securities for 60 days after the exchange becomes effective, which is expected to assist cash flow and liquidity.
Vivos Therapeutics (NASDAQ: VVOS) reported first quarter 2026 revenue of approximately $5.1 million, up 70% year over year, driven mainly by sleep testing services and its SCN acquisition. Gross profit rose to $3.1 million with a 60% gross margin, while net loss widened to $7.8 million.
Operating expenses increased to $9.7 million, including about $0.9 million in non-recurring professional fees. Oral appliance unit sales grew 42% to 5,304, though legacy VIP appliance revenue declined. Cash was $2.1 million and stockholders’ equity showed a $1.1 million deficit at March 31, 2026.